RANDOMIZED STUDY OF DOXORUBICIN PLUS CISPLATIN VS CIRCADIAN-TIMED DOXORUBICIN

III、IV期或复发的子宫内膜癌患者以前没有 接受化疗的患者符合研究条件。 这项研究的目的是确定昼夜节律的阿霉素- 顺铂化疗可显著改善卵巢癌的发生频率 客观反应、无进展间期持续时间和 与标准阿霉素-顺铂相比的生存时间 化疗，并确定是否有任何显著差异 昼夜节律给药阿霉素-顺铂的毒性， 阿霉素-顺铂化疗与标准给药的比较 化疗。这项研究是一项随机研究和随机化， 将对这两种处理进行同等概率的处理 在所有GOG中平衡分配方案顺序的方案 参与这项研究的机构。我会估计一下 这所医院的20名病人。

Women with stage III, IV or recurrent endometrial carcinoma previously not treated with chemotherapy are eligible for the study. The aims of this study are to determine if circadian-timed doxorubicin- cisplatin chemotherapy offers significant improvement in the frequency of objective response, the duration of progression-free interval and the length of survival as compared to standard doxorubicin-cisplatin chemotherapy and to determine if there are any significant differences in toxicity between circadian-timed delivery of doxorubicin-cisplatin, chemotherapy versus standard delivery of doxorubicin-cisplatin chemotherapy. This study is a randomized study and randomization with equal probabilities will be carried out to each of the two treatment regimens balancing the sequence of assigned regimens within all GOG institutions participating in this study. I would estimate the accrual of twenty patients from this institution.